Risk Assessment Report on a new psychoactive substance: methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-car- bonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Series type: Risk assessments


This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en- PINACA. The report is intended for policymakers and decision-makers in the institutions of the EU.

Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style. The final report will be available in due course.

Download as PDF

Table of contents

  • Statement regarding the United Kingdom
  • Contents
  • Introduction
  • Background
  • Pharmacological and toxicological properties
  • Health risks
  • Social risks
  • Extent and patterns of use, availability and potential for diffusion
  • Commercial and industrial uses, the extent of such use and its use for scientific research and developmental purposes
  • Other relevant information
  • Conclusion